ADMA BiologicsADMA +0.05%64 Interest Coverage is 23.95 as of Mar. 2026, which is 140% above its 10-year median of 9.98. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.04 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 376 Biotechnology companies, ADMA Biologics ranks worse than 62.77% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. ADMA Biologics's
Operating Income
for the
three
months ended in Mar. 2026 was $50.3 Mil. ADMA Biologics's Interest Expense for the
three
months ended in Mar. 2026 was $-2.1 Mil.
ADMA Biologics's interest coverage for the quarter that ended in Mar. 2026 was 23.95.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for ADMA Biologics's Interest Coverage or its related term are showing as below:
ADMA'
s Interest Coverage Range Over the Past 10 Years
Min: 0.86 Med: 9.98 Max: 28.59
Current: 28.59
ADMA's Interest Coverage is ranked worse than 62.77% of 376
companies
in the Biotechnology industry
Industry Median: 110.86
vs ADMA: 28.59
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
ADMA Biologics Interest Coverage Related Terms
ADMA Biologics Interest Coverage Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ADMA vs ZLAB, HRMY, STOK: Interest Coverage Comparison
For the Biotechnology subindustry, ADMA Biologics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Interest Coverage of 23.95 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on ADMA Biologics and its competitors. This is 140% above median its historical median of 9.98. Over the past decade, ADMA Biologics' Interest Coverage has ranged from 0.86 to 28.59. According to the industry distribution chart, ADMA Biologics ranks #236 out of 376 companies in the Biotechnology industry, placing it in the top 62.8%.
Is ADMA Biologics' Interest Coverage too high?
ADMA Biologics' current Interest Coverage of 23.95 is 140% above median its 10-year median of 9.98. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 28.59. The Biotechnology industry median Interest Coverage is 110.86. ADMA Biologics' value of 23.95 is 78.4% below this industry median. Based on the distribution chart, ADMA Biologics ranks #236 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Interest Coverage compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #236 out of 376 companies for Interest Coverage. This places ADMA Biologics in the lower half of its industry. The industry median Interest Coverage is 110.86. ADMA Biologics' value of 23.95 is 78.4% below this benchmark. Historically, ADMA Biologics' own Interest Coverage has ranged from 0.86 to 28.59 over the past decade. While the company's 10-year median is 9.98 vs. the industry median of 110.86, ADMA Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 110.86, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Interest Coverage of 23.95 is 78.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Interest Coverage is 110.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Interest Coverage is 23.95, which is 140% above median its own 10-year median of 9.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.04, compared to a current price of $9.22 — trading 48.9% below its estimated fair value. The current Interest Coverage is 23.95, which is 140% above median its 10-year median of 9.98 and 78.4% below the Biotechnology industry median of 110.86. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Interest Coverage is 23.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.22 is trading 48.9% below its estimated GF Value™ of $18.04.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Interest Coverage: 23.95 (140% above median its 10-year median of 9.98)
GF Value™: $18.04 vs. price of $9.22 (48.9% below fair value)
Industry Position: 78.4% below the Biotechnology median (#236 of 376)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
